 | |
| Clinical data | |
|---|---|
| Trade names | Atelec (アテレック), Cilaheart, Cilacar |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.162.338 |
| Chemical and physical data | |
| Formula | C27H28N2O7 |
| Molar mass | 492.528 g·mol−1 |
| 3D model (JSmol) | |
| |
Cilnidipine is acalcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, and Korea forhypertension.
It is a calcium antagonist accompanied withL-type andN-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on theN-type calcium channel in addition to acting on theL-type calcium channel.
It was patented in 1984 and approved for medical use in 1995. Cilnidipine is currently being repurposed and developed for use in patients withRaynaud's phenomenon andsystemic sclerosis by Aisa Pharma, a US biopharma development company.[1]
Cilnidipine decreases blood pressure and is used to treat hypertension and itscomorbidities. Due to its blocking action at theN-type andL-type calcium channel, cilnidipine dilates botharterioles andvenules, reducing the pressure in thecapillary bed. Cilnidipine is vasoselective and has a weak directdromotropic effect, a strong vasodepressor effect, and an arrhythmia-inhibiting effect.Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients [The CA-ATTEND study] - the results of a large-scale prospective post-marketing surveillance study of post-stroke hypertensive patients (n = 2667, male 60.4%, 69.0 ± 10.9 years) treated with cilnidipine indicate that cilnidipine was effective in treating uncontrolled blood pressure and was well tolerated in post-stroke hypertensive patients.[2]The Ambulatory Blood Pressure Control and Home Blood Pressure (Morning and Evening) Lowering By N-Channel Blocker Cilnidipine (ACHIEVE-ONE) trial is a large-scale (n=2319) clinical study on blood pressure (BP) and pulse rate (PR) in the real world with use of cilnidipine - this study revealed that Cilnidipine significantly reduced BP and PR in hypertensive patients at the clinic and at home, especially with higher BP and PR in the morning. Cilnidipine is currently being studied in the RECONNOITER study in Australia for its effect on Raynaud's and other manifestations of disease in patients with Systemic Sclerosis.[3][4]
The side effects could be severe dizziness, fast heartbeat, and swelling of face, lips, tongue, eyelids, hands and feet. Lesser side effects include stomach pain, diarrhea and hypotension.
Peripheral edema, a common side effect from the use ofamlodipine, was reduced when patients were shifted to cilnidipine.[5]
In India, it is sold under the brand name Cinod, Cilacar, Clinblue, Cilaheart, and among others at doses of 5mg–10mg–20mg.[6]
It was jointly developed byFuji Viscera Pharmaceutical Company andAjinomoto, and was approved to enter the market and be used as ananti-hypertensive in 1995.[citation needed]